Onconetix (FRA:J4T) Buyback Yield %: -48.61 (As of Jul. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:J4T Onconetix Inc FRA:J4T
19 GF Score
Price €11,985.00
! 5 Warning Signs
View Full Analysis

What is Onconetix Buyback Yield %?

Onconetix FRA:J4T 19 Buyback Yield % is -48.61 as of Jul. 20, 2026. GuruFocus rates FRA:J4T with a GF Score™ of 19/100. The stock has 5 warning signs investors should review. Among 740 Biotechnology companies, Onconetix ranks worse than 82.7% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Onconetix's current buyback yield was -48.61%.

Onconetix Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Onconetix's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Onconetix Buyback Yield % Chart

Onconetix Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 -1.82 -1.47

Onconetix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -168.49 -133.98 -132.58 -264.31 -33.17

FRA:J4T vs CMND, REVB, PPCB: Buyback Yield % Comparison

For the Biotechnology subindustry, Onconetix's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Onconetix Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Onconetix's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Onconetix's Buyback Yield % falls into.


FRA:J4T
19GF Score
Onconetix Inc FRA:J4T
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Onconetix Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Onconetix's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-0.001 + 5.459) / 371.535
=-1.47%

Onconetix's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-0.001 + 1.183) / 3307.86
=-0.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -48.61 mean?
Onconetix (FRA:J4T) has a Buyback Yield % of -48.61 as of Jul. 20, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Onconetix and its competitors. According to the industry distribution chart, Onconetix ranks #612 out of 740 companies in the Biotechnology industry, placing it in the top 82.7%.
Is Onconetix's Buyback Yield % too high?
Onconetix's current Buyback Yield % is -48.61. Based on the distribution chart, Onconetix ranks #612 out of 740 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Onconetix has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Onconetix's Buyback Yield % compare to CMND and REVB?
According to the Biotechnology industry distribution chart, Onconetix ranks #612 out of 740 companies for Buyback Yield %. This places Onconetix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Onconetix and its competitors. Onconetix's current Buyback Yield % is -48.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onconetix stock overvalued right now?
Onconetix (FRA:J4T) has a current Buyback Yield % of -48.61. The current Buyback Yield % is -48.61. Onconetix's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Onconetix (FRA:J4T), the current Buyback Yield % is -48.61 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Onconetix Business Description

Other Exchanges ONCO:USA
Address 201 E. Fifth Street, Suite 1900, Cincinnati, OH, USA, 45202
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
19GF Score

Get the complete analysis for FRA:J4T

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11,985.00
Price